Lundbeck to buy Prexton in potential $1bn+ deal

By Staff Reporter

- Last updated on GMT

GettyImages: Devonyu
GettyImages: Devonyu
The Danish drugmaker says it will take responsibility for commercial manufacturing after acquiring Parkinson’s disease candidate foliglurax in a deal worth up to €905m ($1.1bn).

Prexton Therapeutics BV lead candidate is foliglurax, a small-molecule positive allosteric modulator of group III metabotropic glutamate receptor 4 (mGluR4 PAM), for the potential oral treatment of Parkinson's disease.

“Parkinson’s disease is characterized by an imbalanced neuronal stimulation,”​ an H. Lundbeck A/S spokesperson told this publication. “Foliglurax is a compound which controls glutamate release in the brain and in turn correct the symptoms of Parkinson’s disease.”

The candidate is in Phase II clinical studies but Lundbeck “will acquire the full IP of Prexton”​ and hopes to take it through to commercialisation.

Prexton does not have any internal manufacturing capacity, we were told, and “Lundbeck will take care of the large scale production”​ going forward.

Under terms of the acquisition, Lundbeck will pay €100m upfront, along with potential future payments of up to €805m in development, regulatory and sales milestones.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Related suppliers

Follow us

Products

View more

Webinars